AbbVie dodges hedge fund lawsuit over failed $55B Shire pursuit Sanofi dumps Principia Biopharma's San Francisco labs with plans to immediately cut 38 jobs Fitbit, Apple user data exposed in breach impacting 61M fitness tracker records Another death blights Astellas' $3B Audentes buy as FDA slaps clinical hold on the test Takeda eyes vaccine business growth amid COVID-19 partnerships and dengue progress, CEO says Mesa Labs puts $300M on the table for genetic testing developer Agena Bioscience Survey: Employers rethinking return-to-work plans as COVID-19 surges Biohaven's ambitious Nurtec ODT marketing strategy pays dividends with doctors in migraine market: analyst Medtronic launches AI pilot program to tackle race, gender disparities in cardiac care CMS wants to pull Trump-era pathway that speeds up Medicare coverage of breakthrough medical devices After regulatory nods, Johnson & Johnson says latest Ebola vaccine data could support prophylactic use Majority of hospitals stumbled on public health reporting before the strain of a global pandemic COVID-19 tracker: Arizona sues Biden admin over vaccine rules; RedHill's COVID hopeful fails late-stage test Featured Story | By Eric Sagonowsky AbbVie faced no shortage of criticism and questioning over its decision to abandon its proposed $55 billion Shire buyout back in 2014. But after years of legal back-and-forth, the company has escaped one high-profile case from hedge funds that alleged the company misled them about its true intentions. read more |
| |
|---|
|
Top Stories By Noah Higgins-Dunn In a one-two punch for Principia Biopharma, Sanofi plans to shutter the company's San Francisco-based drug discovery laboratories by the end of the year and immediately cut 38 jobs, the French pharma told Fierce Biotech. read more By Heather Landi An unsecured database containing over 61 million records related to fitness trackers and wearables exposed Apple and Fitbit users' data online. read more By Ben Adams Astellas has seen a fourth death in its gene therapy trial of an experimental drug gained through the pharma’s $3 billion buyout of biotech Audentes. read more By Angus Liu Takeda is helping Moderna and Novavax make their COVID-19 vaccines available in Japan. With those new products and about a decade’s worth of progress on its dengue shot, Takeda's CEO sees vaccines becoming a bigger part of the drugmaker’s business going forward. read more By Andrea Park Within the first year of the buyout, Mesa said it expects Agena to bring in between $63 million and $67 million in revenue, plus an additional $3 million to $5 million in COVID testing revenue. read more By Paige Minemyer The surge of COVID-19 cases caused by the delta variant has employers rethinking their plans for returning to work—and planning for business to stabilize later than expected, a new survey shows. read more By Beth Snyder Bulik Biohaven went all in on marketing its added preventive indication for oral migraine med Nurtec. And now it’s reaping the rewards with doctors. Three months post approval, 96% of neurologists were aware of the brand, while 65% are “highly familiar” with it, according to Spherix Global Insights' post-launch report. read more By Conor Hale In collaboration with the artificial intelligence developer Mpirik and the healthcare quality tracking company Vizient, the effort will focus on addressing disparities in care across gender and race. read more By Robert King CMS aims to pull a Trump-era pathway that would grant Medicare coverage for breakthrough medical devices as soon as they are authorized by the FDA. read more By Kevin Dunleavy After scoring a European approval and a prequalification from the World Health Organization, the Ebola regimen from Johnson & Johnson has turned in another trial win. The two-shot vaccine, which combines J&J’s Zabdeno followed eight weeks later by Bavarian Nordic’s Mvabea, was safe, well tolerated and produced a strong immune response. The results "support the potential prophylactic use," J&J said. read more By Dave Muoio A recent data brief from the ONC suggests that most hospitals had issues electronically exchanging information with public health agencies well before the strain of a global pandemic. read more By Noah Higgins-Dunn,Kevin Dunleavy,Fraiser Kansteiner A World Health Organization-backed vaccine hub is working to produce Moderna's mRNA jab for the continent. Arizona is suing the Biden administration over its sweeping vaccine order issued last week. RedHill Biopharma's experimental SK2 inhibitor opaganib failed its late-stage test. Plus more. read more |
